Hematologic Oncology | Specialty

Hairy Cell Leukemia: Incidence and Presentation

June 18th 2019

Dr. O'Brien on the Phase III ASCEND Trial in CLL

June 16th 2019

Susan M. O’Brien, MD, associate director for Clinical Services, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, discusses the phase III ASCEND trial in chronic lymphocytic leukemia.

New Macrophage Immune Checkpoint Strategy Shows Promise in AML and MDS

June 16th 2019

Hu5F9-G4 (5F9), a first-in-class antibody targeting CD47, used as monotherapy or in combination with standard azacitidine was well tolerated and provided deep and durable responses in patients with acute myeloid leukemia or myelodysplastic syndrome, according to findings from a phase IB study presented at the 2019 European Hematology Association Congress.

Dr. Roboz on the QuANTUM-R Trial in AML

June 16th 2019

Gail Roboz, MD, a professor of medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell MedicineNewYork-Presbyterian Hospital, discusses the QuANTUM-R trial, which evaluated quizartinib versus chemotherapy in patients with relapsed/refractory FLT3-mutant acute myeloid leukemia.

Second-Generation FLT3 Inhibitors Are Future of Relapsed/Refractory FLT3-Mutant AML Treatment

June 15th 2019

Naval G. Daver, MD, discusses the data that support quizartinib so far, ongoing investigations with this drug in the frontline setting, and the potential for the agent to be approved by the FDA.

Imetelstat Provides Durable Transfusion Independence in Lower-Risk Relapsed/Refractory MDS

June 14th 2019

Imetelstat treatment may allow patients with debilitating anemia due to myelodysplastic syndrome to remain transfusion-free for extended periods of time.

Elotuzumab Triplet Continues to Show Survival Benefit in Relapsed/Refractory Myeloma

June 14th 2019

The triplet regimen of elotuzumab plus pomalidomide and dexamethasone led to a 46% reduction in the risk of death compared with pomalidomide/dexamethasone alone in patients with relapsed/refractory multiple myeloma, according to updated findings of the phase II ELOQUENT-3 trial.

Dr. Rule on the MabCute Study in Indolent Non-Hodgkin Lymphoma

June 14th 2019

Simon Rule, MD, PhD, Plymouth University Medical School, discusses results of the phase III MabCute study evaluating subcutaneous rituximab as maintenance after standard subcutaneous rituximab induction and maintenance in patients who have relapsed or refractory indolent non-Hodgkin lymphoma.

Dr. Chari on the INSIGHT MM Study on Multiple Myeloma

June 14th 2019

Ajai Chari, MD, Icahn School of Medicine at Mount Sinai, discusses INSIGHT MM (NCT02761187), the largest global, prospective, non-interventional, observational study on multiple myeloma to date.

Innovation Fuels Survival Gains in Multiple Myeloma

June 12th 2019

While the expansion of therapeutic opportunity in multiple myeloma has been incremental in some ways, it’s been continuous and, when seen in aggregate, the impact is considerable.

Attaining MRD Among Next Steps in the ALL Paradigm

June 12th 2019

Nelson Jen An Chao, MD, discusses current understandings of minimal residual disease and the therapies that have helped promulgate its utility in acute lymphoblastic leukemia.

FDA Approves Polatuzumab Vedotin for DLBCL

June 10th 2019

The FDA has granted an accelerated approval to polatuzumab vedotin (Polivy) for use in combination with bendamustine and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma.

Navigating Between High- and Low-Intensity Treatment Options in AML

June 9th 2019

Thomas W. LeBlanc, MD, shares advice for community oncologists on to how to better navigate the complex treatment paradigm of acute myeloid leukemia.

Novel Cedazuridine/Decitabine Combo Meets Primary Endpoint in Phase III MDS/CMML Trial

June 8th 2019

The fixed-dose combination of cedazuridine and decitabine demonstrated decitabine exposure equivalence of total 5-day dosing compared with intravenous decitabine in patients with intermediate- and high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia, meeting the primary endpoint of the phase III ASCERTAIN trial.

TKI Discontinuation Still an Unclear Picture in CML

June 7th 2019

Lindsay A.M. Rein, MD, discusses the current state of TKI discontinuation in patients with chronic myeloid leukemia.

Ixazomib Phase III Trial Discontinued in AL Amyloidosis

June 6th 2019

Ixazomib in combination with dexamethasone did not demonstrate a significant improvement in overall hematologic response compared with standard therapy in patients with relapsed/refractory systemic light-chain amyloidosis, missing one of two primary endpoints in the phase III TOURMALINE-AL1 trial and leading to discontinuation of the study.

Expert Highlights Current State of Severe Aplastic Anemia

June 6th 2019

Carlos Manuel de Castro III, MD, highlights current treatment approaches for severe aplastic anemia and some of the unmet needs that still exist.

FDA Grants Momelotinib Fast Track Designation in Myelofibrosis

June 5th 2019

The FDA has granted momelotinib a fast track designation for use as a treatment of patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.

Targeted Therapies Advance Treatment in AML, But Toxicity Challenges Remain

June 5th 2019

Harry P. Erba, MD, PhD, provides insight into how to navigate through the targeted therapies available in the treatment of acute myeloid leukemia and discussed the work that lies ahead in this space.

FDA Accepts BLA for Luspatercept in MDS, Grants Priority Review in Beta-Thalassemia

June 5th 2019

The FDA has accepted a biologics license application for the investigational erythroid maturation agent luspatercept for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndromes-associated anemia who have ring sideroblasts and require red blood cell (RBC) transfusions, as well as for adult patients with beta-thalassemia-associated anemia who require RBC transfusions.